PMID- 25220535
OWN - NLM
STAT- MEDLINE
DCOM- 20150226
LR  - 20220316
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Print)
IS  - 1347-9032 (Linking)
VI  - 105
IP  - 11
DP  - 2014 Nov
TI  - Serum chromogranin A is a useful marker for Japanese patients with pancreatic 
      neuroendocrine tumors.
PG  - 1464-71
LID - 10.1111/cas.12533 [doi]
AB  - Although chromogranin A (CGA) is a useful marker for pancreatic neuroendocrine 
      tumors (pNET) in the West, its usefulness in Japanese populations is unclear. To 
      assess this, we evaluated the serum CGA levels in 189 patients with various 
      pancreatic diseases, including proven pNET (n = 69), pancreatic cancer (PC) (n = 
      50), chronic pancreatitis (CP) (n = 50) and autoimmune pancreatitis (AIP) (n = 
      20), and 112 normal controls (controls) using an ELISA kit. The mean CGA level of 
      patients with pNET was significantly higher than any of the other groups (407.8 +/- 
      984.6 ng/mL [pNET] vs 91.8 +/- 101.8 ng/mL [PC], 93.6 +/- 57.5 ng/mL [CP], 69.9 +/- 
      52.4 ng/mL [AIP] and 62.5 +/- 48.3 ng/mL [controls]). Limiting the analysis to 
      patients not using proton pump inhibitors (PPI), the CGA level of patients with 
      PC or CP was not significantly different compared with the controls. Discriminant 
      analysis revealed that the best cut-off value of CGA to distinguish patients with 
      pNET from the controls was 78.7 ng/mL, with a sensitivity and specificity of 
      53.6% and 78.6%, respectively. In patients with pNET, significant factors 
      associating with elevated CGA levels were tumor classification, tumor size, and 
      the presence of liver metastases in univariate analysis as well as PPI use and 
      the presence of liver metastases in multivariate analysis. We show that CGA is a 
      useful marker for diagnosing pNET in Japanese populations and for distinguishing 
      patients with pNET from patients with other pancreatic diseases. The increased 
      use of CGA in Japan will likely be a helpful tool in managing these patients, as 
      found in the West.
CI  - (c) 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on 
      behalf of Japanese Cancer Association.
FAU - Hijioka, Masayuki
AU  - Hijioka M
AD  - Department of Medicine and Bioreguratory Science, Graduate School of Medical 
      Sciences, Kyushu University, Fukuoka, Japan.
FAU - Ito, Tetsuhide
AU  - Ito T
FAU - Igarashi, Hisato
AU  - Igarashi H
FAU - Fujimori, Nao
AU  - Fujimori N
FAU - Lee, Lingaku
AU  - Lee L
FAU - Nakamura, Taichi
AU  - Nakamura T
FAU - Jensen, Robert T
AU  - Jensen RT
FAU - Takayanagi, Ryoichi
AU  - Takayanagi R
LA  - eng
PT  - Journal Article
DEP - 20141018
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Chromogranin A)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*blood
MH  - Chromogranin A/*blood
MH  - Female
MH  - Humans
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Metastasis
MH  - Neuroendocrine Tumors/*blood/diagnosis
MH  - Odds Ratio
MH  - Pancreatic Neoplasms/*blood/diagnosis
MH  - Prognosis
MH  - ROC Curve
MH  - Reproducibility of Results
MH  - Tumor Burden
MH  - Young Adult
PMC - PMC4462381
OTO - NOTNLM
OT  - Chromogranin A
OT  - Japan
OT  - pancreatic cancer
OT  - pancreatic neuroendocrine tumors
OT  - proton pump inhibitors
EDAT- 2014/09/16 06:00
MHDA- 2015/02/27 06:00
PMCR- 2014/11/01
CRDT- 2014/09/16 06:00
PHST- 2014/05/15 00:00 [received]
PHST- 2014/09/05 00:00 [revised]
PHST- 2014/09/07 00:00 [accepted]
PHST- 2014/09/16 06:00 [entrez]
PHST- 2014/09/16 06:00 [pubmed]
PHST- 2015/02/27 06:00 [medline]
PHST- 2014/11/01 00:00 [pmc-release]
AID - 10.1111/cas.12533 [doi]
PST - ppublish
SO  - Cancer Sci. 2014 Nov;105(11):1464-71. doi: 10.1111/cas.12533. Epub 2014 Oct 18.